179 related articles for article (PubMed ID: 7815460)
1. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Hüsken BC; de Jong J; Beekman B; Onderwater RC; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1995; 37(1-2):55-62. PubMed ID: 7497597
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
4. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
6. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
7. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species.
de Jong J; Schoofs PR; Onderwater RC; van der Vijgh WJ; Pinedo HM; Bast A
Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):275-89. PubMed ID: 2166963
[TBL] [Abstract][Full Text] [Related]
8. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
9. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
[TBL] [Abstract][Full Text] [Related]
11. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
13. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
14. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
16. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
[TBL] [Abstract][Full Text] [Related]
17. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
19. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.
Xu LJ; Jin L; Pan H; Zhang AZ; Wei G; Li PP; Lu WY
Acta Pharmacol Sin; 2006 Oct; 27(10):1333-9. PubMed ID: 17007740
[TBL] [Abstract][Full Text] [Related]
20. Cardiac DT-diaphorase contributes to the detoxification system against doxorubicin-induced positive inotropic effects in guinea-pig isolated atria.
Badary OA; Awad AS; Abdel-Maksoud S; Hamada FM
Clin Exp Pharmacol Physiol; 2004 Dec; 31(12):856-61. PubMed ID: 15659049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]